GloviczkiMLDemetresMRSalazarG, et al.Venoactive drugs for venous origin chronic pelvic pain in women: a systematic review. Phlebology2025: 2683555251411027. https://doi.org/10.1177/02683555251411027
2.
GloviczkiMLKakkosSKUrbanekT, et al.The role of venoactive compounds in the treatment of chronic venous disease. J Vasc Surg Venous Lymphat Disord2025; 13(5): 102258. https://doi.org/10.1016/j.jvsv.2025.102258
3.
SoysalMESoysalSVicdanK, et al.A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion. Hum Reprod2001; 16(5): 931–939. https://doi.org/10.1093/humrep/16.5.931
4.
ShokeirTAmrMAbdelshaheedM. The efficacy of implanon for the treatment of chronic pelvic pain associated with pelvic congestion: 1-year randomized controlled pilot study. Arch Gynecol Obstet2009; 280(3): 437–443. https://doi.org/10.1007/s00404-009-0951-1
5.
WhiteleyMSImranHA. Pelvic venous disorders (PeVD) are not well represented in obstetrics and gynaecology journals. Phlebology2025; 40(6): 441–445. https://doi.org/10.1177/02683555251314285
6.
PietrzyckaAKózkaMUrbanekT, et al.Effect of micronized purified flavonoid fraction therapy on Endothelin-1 and TNF-α levels in relation to antioxidant enzyme balance in the peripheral blood of women with varicose veins. Curr Vasc Pharmacol2015; 13(6): 801–808. https://doi.org/10.2174/1570161113666150827124714
7.
GavrilovSGKaralkinAVMoskalenkoYP, et al.Effects of venoactive drug therapy and ovarian vein interventions on vasoactive neuropeptide and cytokine levels in patients with pelvic venous disorders. Ann Vasc Surg2024; 108: 466–474. https://doi.org/10.1016/j.avsg.2024.05.027
8.
GavrilovSGKaralkinAVMoskalenkoYP, et al.Efficacy of two micronized purified flavonoid fraction dosing regimens in the pelvic venous pain relief. Int Angiol2021; 40(3): 180–186. https://doi.org/10.23736/s0392-9590.21.04579-x
9.
GavrilovSGMoskalenkoYPGrishenkovaAS, et al.Venoactive drug treatment for patients with pelvic varicose veins: results of the single-center, randomized, open-label study (VENOTREAT). Vasc Med2025; 30(5): 590–598. https://doi.org/10.1177/1358863x251362200
